# A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver

> **NCT00906373** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 47 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)
- **BIOLOGICAL:** IMC-A12 (cixutumumab) - 20 mg/kg
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT00906373
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2012-10
- **Final completion:** 2014-05
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2018-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00906373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00906373, "A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00906373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*